European Journal of Pharmacology p. 477 - 484 (1996)
Update date:2022-08-05
Topics:
Halmos, Therese
Santarromana, Monique
Antonakis, Kostas
Scherman, Daniel
A limitation of the use of chemotherapeutic agents against intracerebral tumors lies on their poor uptake into the central nervous system. An approach to enhance brain delivery is to design agents that are transported into the brain by one of the saturable nutrient carriers of the blood-brain barrier, the highly efficient brain and erythrocyte glucose transporter isoform GLUT1. Since the GLUT1 hexose transporter of the blood-brain barrier is also present on erythrocytes, new compounds designed to be transported by the GLUT1 transporter were studied on human erythrocytes, which represent unique, easily accessible human GLUT1 expressing cells. In this paper we describe the synthesis of four glucose chlorambucil derivatives, namely methyl 6-O-4[bis(2-chloroethyl)amino]benzenebutanoyl-β-D- glucopyranoside (3), 6- O-4-[bis(2-chloroethyl)amino]benzenebutanoyl-D- glucopyranose (6), methyl 6-{4-[bis(2- chloroethyl)amino]benzenebutanoylamido}-6-deoxy-β-D- glucopyranoside (9) and 6-{4-[bis(2-chloroethyl)amino]benzenebutanoyl amido}-6-deoxy-D-glucopyranose (10), and the study of their interactions with the GLUT1 transporter of the human erythrocytes. All four compounds were able to inhibit [14C]glucose uptake in a concentration-dependent manner. One of them, compound 6, exhibited an approximately 160-fold higher inhibition of [14C]glucose uptake by the GLUT1 transporter than glucose itself. Compound 6 was also able to inhibit [3H]cytochalasin B binding to erythrocytes with approximately 1000-fold higher efficacy than does glucose. The inhibition of glucose uptake was entirely reversible, indicating that it was not due to alkylation of a nucleophilic group of the hexose transporter. The above results suggested specific interactions of compound 6 with the hexose transporter protein. Uptake studies of [14C]compound 6 indicated, in addition, some non-specific interactions with intact and open erythrocyte membranes: only a small amount of the bound [14C]compound 6 can be displaced by cytochalasin B. Collectively, these findings led us to conclude that the interactions of compound 6 with GLUT1 are presumably that of a non-transported inhibitor.
View MoreShenyang NovPharm Technology Co., Ltd.
Contact:.+86-24-24165786
Address:Room 306, Hongjin Mansion, No. 36-1, Wanliutang Rd., Shenhe District, Shenyang, Liaoning, P.R.C.
Binzhou Holly Pharmaceutical Co.,Ltd.
Contact:74517
Address:No.15 Dapu Road,Huangpu District Shanghai,P.R.China
Jinan Jiaquan Chemical Co.,Ltd
Contact:+86-531-62318366
Address:Room 502 of Yidonghuayuan No.601 Huaxin Road Licheng District Jinan China
Shandong Yuanli Science and Technology Co., Ltd.
Contact:86-0536-6777557
Address:Zhuliu Industiral Park,Changle County
Shanghai Yurui Biotechnology(Anyang) Pharmaceutical Co., Ltd
Contact:+86-0372-3662335 +86-0372-3661988
Address:hanling industrial park anyang
Doi:10.1016/S0040-4039(96)02369-6
(1997)Doi:10.1080/00397919708004810
(1997)Doi:10.1039/a604966d
(1997)Doi:10.1021/ja01846a016
(1941)Doi:10.1002/anie.201202623
(2012)Doi:10.1055/s-0032-1318365
(2013)